Intelligence Platform
Patents
Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 11479613
Methods for treating cancer or modulating T cells or NK cells in a subject by administerin
granted patentUS 11479614
Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by
granted patentUS 11473060
Compositions and methods for differentiating stem cells into NK cells
granted patentUS 11471491
Materials and methods for engineering cells and uses thereof in immuno-oncology
granted patentUS 11472884
Humanized BCMA antibody and BCMA-CAR-T cells
granted patentUS 11464807
Genetically engineered hematopoietic stem cells and uses thereof
granted patentUS 11458212
Molecular imaging of cancer cells in vivo
granted patentUS 11458171
Engineering stem cells for cancer therapy
granted patentUS 11459560
Methods and compositions for reprogramming cells
granted patentUS 11459372
Gene-edited natural killer cells
granted patentUS 11453861
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
granted patentUS 11446357
Method for treating disease using FOXP3+CD4+ T cells
granted patentUS 11446302
Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutat
granted patentUS 11441184
Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem
granted patentUS 11433103
Universal donor cells
granted patentUS 11434505
Universal donor cells
granted patentUS 11419883
Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
granted patentUS 11421010
T cells expressing membrane-anchored IL-12 for the treatment of cancer
granted patentUS 11400118
Methods for production of platelets from pluripotent stem cells and compositions thereof
granted patentUS 11401510
Generation of airway basal stem cells from human pluripotent stem cells
granted patentUS 11400116
Systems and methods for targeting cancer cells
granted patentUS 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted patentUS 11389481
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells target
granted patentUS 11389485
Genetically engineered hematopoietic stem cells and uses thereof
granted